Eckert & Ziegler stock gains 1.30 percent on October 5

Published on 10/05/2026 at 13:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock traded at EUR 12.51 on October 5, 2026, as the company entered the second half with confirmed annual targets. H1 revenue was EUR 149.3 million.

Pop-Art-Comicbild eines Wissenschaftlers mit leuchtend grünem Radioisotop im Nuklearmedizin-Labor — Eckert & Ziegler DE0005659700 Medizintechnik: Pop-Art-Comic mit Wissenschaftler im Nuklearmedizin-Labor und leuchtender Radioisotopen-Ampulle, Illustration mit AI erstellt.

Eckert & Ziegler stock (ISIN DE0005659700) was trading at EUR 12.51 on Xetra on October 5, 2026, up 1.30 percent from the prior close. The latest operating picture combines flat first-half revenue with a confirmed full-year outlook, leaving second-half execution as the key test.

First-half revenue stayed flat

According to Quartr on September 25, 2026, Eckert & Ziegler reported H1 2026 revenue of EUR 149.3 million, compared with EUR 148.8 million in H1 2025. That represents growth of 0.3 percent, while the adjusted EBIT margin came under pressure as adjusted EBIT fell 6 percent from EUR 35.4 million to EUR 33.3 million.

The earnings mix was more constructive below the revenue line. Net income rose 5 percent to EUR 22.4 million, and the Medical segment delivered better operating performance while Isotope Products remained the weaker division.

Guidance puts pressure on the second half

Parqet reported on September 16, 2026, that management retained its 2026 targets of EUR 320 million in revenue and EUR 80 million in adjusted EBIT. Against the EUR 33.3 million adjusted EBIT achieved in the first half, the company must generate EUR 46.7 million in the second half to reach that annual target.

The arithmetic makes product mix and delivery timing more important than the small reported revenue increase. The investor presentation also points to radiopharmaceutical demand as a growth driver, while weaker industrial activity has weighed on Isotope Products.

Analysts see a wide valuation gap

According to Investing.com, three analysts carried Buy ratings, producing a Strong Buy consensus and an average 12-month price target of EUR 21.60. The highest target was EUR 23.00 and the lowest was EUR 20.30; the average target lies 72.7 percent above the EUR 12.51 Xetra price.

The market capitalization was EUR 782.8 million on October 5, 2026, while the 52-week range stood at EUR 12.01 to EUR 23.25. The current quote is EUR 0.50 above the yearly low, placing execution against the confirmed targets at the center of the stock story.

Stock trades above yearly low

Eckert & Ziegler stock was trading at EUR 12.51 on Xetra at 1:11 p.m. CEST on October 5, 2026, with an intraday range of EUR 12.14 to EUR 12.51 and a 52-week range of EUR 12.01 to EUR 23.25.